Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: A short report

Virology Journal

Volumn 6, Issue , 2009, Pages

  Yang, Jin ^a   Zhao, Lian San ^b  

^a Affiliated Shenzhen Sixth Hospital of Guangdong Medical University   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CHINESE; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; LEUKOPENIA; MALE; MONOTHERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; BLOOD; MIDDLE AGED; VIROLOGY;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; YOUNG ADULT;

EID: 68149139470     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-97     Document Type: Article

References (14)

1. Viral hepatitis B. CL Lai V Ratziu MF Yuen T Poynard, Lancet 2003 362 2089 94 10.1016/S0140-6736(03)15108-2 14697813 (Pubitemid 38032767)
2. Treatment of chronic hepatitis B. SR Mohanty SS Kupfer Khianiv, Nat clin pract Gastroenterol Hepato 2006 3 446 458 10.1038/ncpgasthep0550 (Pubitemid 44203798)
3. Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. HI Yang SN Lu YF Liaw SL You CA Sun LY Wang CK Hsiao PJ Chen DS Chen CJ Chen, N Engl J Med 2002 347 168 74 10.1056/NEJMoa013215 12124405 (Pubitemid 34764820)
4. Personal view: the management of chronic hepatitis B infection. M Sherman, Aliment Pharmacol Ther 2006 23 857 869 10.1111/j.1365-2036.2006.02840.x 16573788
5. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. GV Papatheodoridis E Manesis SJ Hadziyannis, J Hepatol 2001 34 306 13 10.1016/S0168-8278(00)00094-5 11281561 (Pubitemid 32176454)
6. EASL International Consensus Conference on Hepatitis B: 1314 September, 2002 Geneva, Switzerland: consensus statement(long version). J Hepatol 2003 39 Suppl 1 S3 S25 14708673
7. Chronic hepatitis B. AS Lok BJ McMahon, Hepatology 2007 45 507 39 10.1002/hep.21513 17256718 (Pubitemid 46374607)
8. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. P Bailon A Palleroni CA Schaffer CL Spence WJ Fung JE Porter GK Ehrlich W Pan ZX Xu MW Modi A Farid W Berthold M Graves, Bioconjug Chem 2001 12 195 202 10.1021/bc000082g 11312680 (Pubitemid 32235471)
9. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. CM Perry B Jarvis, Drugs 2001 61 2263 88 10.2165/00003495-200161150-00013 11772139
10. Pegylated interferons for chronic hepatitis B. A Craxi WG Cooksley, Antiviral Res 2003 60 87 89 10.1016/j.antiviral.2003.08.015 14638403 (Pubitemid 37452451)
11. Peginterferon alpha-2a(40 KD): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. WG Cooksley T Piratvisuth SD Lee V Mahachai YC Chao T Tanwandee A Chutaputti WY Chang FE Zahm N Pluck, J Viral Hepatitis 2003 10 298 305 10.1046/j.1365-2893.2003.00450.x (Pubitemid 36801917)
12. Antiviral therapy and resistance with hepatitis B virus infection. HL Tillmann, World J Gastroenterol 2007 13 125 140 17206760
13. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. P Marcellin GK Lau F Bonino P Farci S Hadziyannis R Jin ZM Lu T Piratvisuth G Germanidis C Yurdaydin M Diago S Gurel MY Lai P Button N Pluck, N Engl J Med 2004 351 1206 17 10.1056/NEJMoa040431 15371578 (Pubitemid 39296307)
14. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. GK Lau T Piratvisuth KX Luo P Marcellin S Thongsawat G Cooksley E Gane MW Fried WC Chow SW Paik WY Chang T Berg R Flisiak P McCloud N Pluck, N Engl J Med 2005 352 2682 95 10.1056/NEJMoa043470 15987917 (Pubitemid 41007823)